Chronic hepatitis B is a long-term infection caused by the hepatitis B virus that affects the liver and requires ongoing care, regular monitoring, and, in many cases, specific treatments to prevent serious complications like cirrhosis or liver cancer, though not everyone needs medication immediately.

How Medical Care Helps People Living with Hepatitis B

The main purpose of treating chronic hepatitis B is to protect the liver from ongoing damage and reduce the risk of developing serious complications. When someone is diagnosed with this infection, the first goal is to prevent the disease from progressing to cirrhosis, which means severe scarring of the liver, or hepatocellular carcinoma, a type of liver cancer. Treatment also aims to prevent liver failure, a life-threatening condition where the liver can no longer perform its essential functions.^[1][2]

Not everyone who has chronic hepatitis B needs to start taking medication right away. The decision to begin treatment depends on several factors, including how active the virus is in the body, the health of the liver, the person’s age, and whether they have other medical conditions. Some people can be monitored regularly without taking drugs, while others require antiviral therapy to control the virus and slow down liver damage. Healthcare providers use blood tests and imaging studies to decide when treatment should begin.^[3][4]

The medical approach to chronic hepatitis B includes both treatments that have been approved by health authorities and used for many years, as well as new experimental therapies being tested in clinical trials around the world. Standard treatments focus on reducing the amount of virus in the blood and decreasing inflammation in the liver. Meanwhile, researchers are working on innovative drugs that may one day achieve what is called a “functional cure,” meaning the virus becomes permanently inactive even after treatment stops.^[5][6]

Standard Treatment for Chronic Hepatitis B

The treatments that doctors prescribe most often for chronic hepatitis B fall into two main categories: antiviral tablets taken daily and injectable medications called interferons. Each type works differently and is chosen based on the patient’s individual situation, including their age, liver condition, and whether they are planning to have children.^[7][8]

Oral Antiviral Medications

Most people with chronic hepatitis B who need treatment will take daily pills known as nucleos(t)ide analogues. These drugs work by stopping the hepatitis B virus from making copies of itself inside liver cells. By reducing the amount of virus in the blood, known as the viral load, these medications help decrease liver inflammation and prevent further scarring. Over time, this allows the liver to heal from previous damage.^[9][10]

Common antiviral medications approved for chronic hepatitis B include entecavir and tenofovir. Both drugs are highly effective at suppressing the virus and have a low risk of the virus developing resistance, meaning the medication continues to work over many years. These medicines are generally taken once a day, and many people tolerate them well with few side effects. Some patients may experience mild symptoms such as headache, fatigue, or digestive discomfort, but serious side effects are uncommon.^[11][12]

Treatment with oral antivirals is usually long-term, often lasting several years or even for life. The goal is to keep the virus suppressed to very low or undetectable levels in the blood. When the viral load drops to these levels, liver inflammation decreases, fibrosis may improve, and the risk of liver cancer is reduced. However, stopping treatment too early can cause the virus to become active again, which may lead to a flare-up of liver inflammation and worsening disease.^[13][14]

Interferon-Based Therapy

Another treatment option is pegylated interferon alfa, which is given as an injection under the skin, usually once a week. Unlike oral antivirals that directly block the virus, interferons work by boosting the body’s immune system to fight the infection more effectively. This type of treatment is typically used for a limited time, usually between six months and one year.^[11][12]

Interferon therapy can lead to the loss of hepatitis B e antigen (HBeAg), a marker in the blood that indicates active viral replication. In some cases, it may even result in the loss of hepatitis B surface antigen (HBsAg), which is a rare outcome that suggests the immune system has gained strong control over the virus. However, interferon treatment is not suitable for everyone. It tends to cause more side effects than oral antivirals, including flu-like symptoms such as fever, fatigue, muscle aches, and mood changes. People with advanced liver disease or cirrhosis are generally not given interferons due to safety concerns.^[9][10]

Monitoring and Adjusting Treatment

People on treatment for chronic hepatitis B require regular monitoring to check how well the medication is working and to watch for side effects. Blood tests are used to measure viral load, liver enzyme levels (such as alanine aminotransferase or ALT), and markers of liver function. Doctors also screen for liver cancer every six months using blood tests for alpha-fetoprotein (AFP) and imaging such as ultrasound. This ongoing surveillance is crucial because even with effective treatment, the risk of liver cancer remains, especially in people with advanced fibrosis or cirrhosis.^[6][15]

Clinical guidelines from organizations such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) recommend starting antiviral treatment when the viral load is above certain thresholds and there is evidence of liver inflammation or fibrosis. For example, treatment is generally advised if the HBV DNA level is above 2,000 international units per milliliter in people who are negative for HBeAg, or above 20,000 IU/mL in those who are HBeAg positive, along with elevated ALT levels or signs of liver damage on biopsy or imaging.^[12][14]

Treatment in Clinical Trials

While current standard treatments can suppress the hepatitis B virus and slow liver disease progression, they do not cure the infection. The virus persists in the liver in a form called covalently closed circular DNA (cccDNA), which acts like a reservoir that allows the virus to rebound if treatment is stopped. Because of this limitation, researchers are actively testing new drugs and treatment strategies in clinical trials with the goal of achieving a functional cure.^[13]

Innovative Therapies Being Studied

Clinical trials for chronic hepatitis B are exploring several different approaches to overcome the limitations of existing treatments. One major area of research focuses on drugs that target the viral cccDNA reservoir or interfere with viral replication at different stages. Another approach involves boosting the patient’s immune response so the body can better control or eliminate the virus.^[13]

Capsid assembly modulators are a new class of antiviral drugs that prevent the hepatitis B virus from forming the protective shell, or capsid, around its genetic material. By disrupting this process, these drugs stop the virus from replicating and may also reduce the pool of cccDNA in infected liver cells. Several capsid inhibitors are currently being tested in Phase 2 and Phase 3 clinical trials. Early results suggest they can reduce viral load, and when combined with existing antivirals, they may lead to better long-term control of the infection.^[13]

RNA interference (RNAi) therapies represent another promising strategy. These treatments use small pieces of genetic material to silence the messenger RNA that the virus uses to produce its proteins, including HBsAg. By reducing the amount of viral antigens, RNAi therapies may help the immune system recognize and attack infected liver cells more effectively. Some RNAi drugs are administered as injections every few weeks or months and are being studied in combination with other antiviral agents.^[13]

Immune modulators are therapies designed to strengthen or restore the body’s immune response against the hepatitis B virus. Chronic infection often leads to immune exhaustion, where the immune cells that should fight the virus become weakened and less effective. Drugs such as checkpoint inhibitors, therapeutic vaccines, and Toll-like receptor agonists aim to reactivate these immune cells. Clinical trials are testing whether these approaches can help patients achieve sustained control of the virus without needing continuous antiviral medication.^[13]

Entry inhibitors are drugs that block the virus from entering liver cells in the first place. By targeting the receptors on the surface of liver cells that the virus uses to gain entry, these medications could prevent new infections of healthy liver cells. Entry inhibitors are in earlier stages of development, mostly Phase 1 and Phase 2 trials, and are being studied alone or in combination with other therapies.^[13]

Trial Phases and What They Mean

Clinical trials progress through several phases before a new drug can be approved for general use. Phase 1 trials are small studies that test a drug’s safety in a small group of people, usually healthy volunteers or patients, to determine the right dose and identify side effects. Phase 2 trials involve more participants and focus on whether the drug works as intended, measuring its effects on viral load, liver enzymes, and other markers of disease activity. Phase 3 trials are large studies that compare the new treatment to the current standard of care to see if it offers additional benefits, such as better viral suppression, fewer side effects, or the possibility of stopping treatment without the virus rebounding.^[11]

Many clinical trials for chronic hepatitis B are conducted in multiple countries, including the United States, Europe, and regions in Asia where hepatitis B is more common. Patients interested in participating in a trial typically need to meet certain criteria, such as having detectable levels of the virus, specific liver enzyme levels, or being treatment-naïve (never treated before) or treatment-experienced. Participation in clinical trials is voluntary, and patients can withdraw at any time.^[11]

Preliminary Results from Ongoing Research

Some early-phase clinical trials have reported encouraging findings. For example, combination therapies that pair a nucleos(t)ide analogue with a capsid assembly modulator or an RNAi drug have led to greater reductions in HBsAg levels compared to standard treatment alone. In certain studies, a small percentage of participants achieved HBsAg loss, which is considered a key milestone toward functional cure. However, these results are preliminary, and longer follow-up is needed to determine whether these effects are sustained over time and whether patients can safely stop treatment.^[13]

Researchers are also investigating the role of combination therapies that include immune modulators. The idea is to suppress the virus with antivirals while simultaneously waking up the immune system to fight the infection. Some trials have shown improvements in immune cell function and viral control, but more research is needed to find the right combinations and treatment durations that maximize benefits while minimizing side effects.^[13]

Most common treatment methods

• Oral antiviral medications (nucleos(t)ide analogues)
  • Entecavir and tenofovir are the most commonly prescribed drugs
  • Taken once daily to suppress viral replication
  • Reduce viral load to undetectable levels and decrease liver inflammation
  • Generally well tolerated with few side effects
  • Treatment is long-term, often lasting years or for life
• Interferon-based therapy
  • Pegylated interferon alfa given as a weekly injection
  • Boosts the immune system to fight the virus
  • Treatment duration is typically 6 to 12 months
  • More side effects than oral antivirals, including flu-like symptoms
  • Not suitable for people with advanced liver disease
• Capsid assembly modulators (in clinical trials)
  • Experimental drugs that prevent the virus from forming its protective shell
  • Aim to reduce viral replication and the cccDNA reservoir
  • Currently being tested in Phase 2 and Phase 3 trials
  • Often studied in combination with standard antivirals
• RNA interference (RNAi) therapies (in clinical trials)
  • Silence viral messenger RNA to reduce production of viral proteins
  • Administered as injections every few weeks or months
  • May help the immune system recognize infected cells
  • Being tested in combination with other treatments
• Immune modulator therapies (in clinical trials)
  • Drugs that reactivate the immune response against the virus
  • Include checkpoint inhibitors, therapeutic vaccines, and Toll-like receptor agonists
  • Aim to achieve sustained viral control without continuous medication
  • In various phases of clinical testing
• Entry inhibitors (in early-phase clinical trials)
  • Block the virus from entering liver cells
  • Prevent new infections of healthy liver cells
  • Mostly in Phase 1 and Phase 2 trials
  • Being studied alone or with other therapies
• Regular monitoring and liver cancer screening
  • Blood tests every 3 to 6 months to measure viral load, ALT, and liver function
  • Alpha-fetoprotein (AFP) blood test and ultrasound every 6 months for liver cancer screening
  • Essential for all people with chronic hepatitis B, whether on treatment or not

Living with Chronic Hepatitis B

People diagnosed with chronic hepatitis B can live long and healthy lives with proper medical care and lifestyle choices. Even if someone is not currently taking medication, there are important steps to protect the liver and support overall health. Regular doctor visits are essential, even when feeling well, because the virus can cause liver damage without symptoms. These visits allow healthcare providers to monitor the disease and start treatment if needed.^[16][17]

Avoiding alcohol is one of the most important actions a person with chronic hepatitis B can take. Any amount of alcohol can accelerate liver damage and increase the risk of cirrhosis and liver cancer. Similarly, recreational drugs, including marijuana, can harm the liver and should be avoided. Studies have shown that marijuana use can speed up the progression to liver scarring in people with chronic hepatitis B.^[16][17]

It is also important to talk with a doctor or pharmacist before taking any over-the-counter medications, herbal remedies, or dietary supplements. Some of these products can be toxic to the liver or interfere with prescribed hepatitis B medications. For example, high doses of acetaminophen (paracetamol) can cause liver damage, especially if the liver is already weakened. Healthcare providers can advise on safe pain relievers and other medications.^[16][17]

Getting vaccinated against hepatitis A is recommended for everyone with chronic hepatitis B. Hepatitis A is another virus that attacks the liver, and people with existing liver disease can become seriously ill if they contract it. The hepatitis A vaccine is safe and effective and can prevent this additional strain on the liver.^[16][19]

Maintaining a healthy diet and regular physical activity can also support liver health. A balanced diet rich in fruits, vegetables, whole grains, and lean proteins provides the nutrients the liver needs to function well. Regular exercise helps maintain a healthy weight, which is important because obesity can worsen liver disease. People with chronic hepatitis B should also avoid exposure to toxic fumes from household chemicals, paint thinners, and other substances that can harm the liver.^[16][17]